Pharma BD Deal Intelligence
Kyowa Hakko Kirin agreed to acquire Scotland-based ProStrakan Group for £292 million (~$473.3M), 130 pence/share — a 41% premium — giving the Japanese group a…
Three years post-deal, KHK doubled down by having ProStrakan acquire Archimedes Pharma for £230M — validating the original 2011 thesis of using ProStrakan as…
Kyowa Kirin divested Sancuso to Cumberland Pharmaceuticals as it refocused North American resources on rare-disease and oncology pipeline assets — long-term…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Kyowa Hakko Kirin acquired UK specialty pharma ProStrakan for £292M (~$474M), 130p/share, a 41% premium. Deal gave KHK a Western commercial platform with Sancuso and supportive-care oncology products. Closed April 21, 2011.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Kyowa Hakko Kirin Co., Ltd. / ProStrakan Group plc (this deal) | 2011 | $474M | 44 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2011 deals · Oncology deals